“Most importantly, the improvement that they were able to get during the first couple of years is sustained, whereas what we expect in untreated men [is that] their erectile function…keeps on deteriorating,” says Karim Sultan Haider, MD.
In this video, Karim Sultan Haider, MD, discusses the background and findings of the study, “Long-term Testosterone Therapy Improves Erectile Function and Reduces Mortality in Men with Hypogonadism and Type 2 Diabetes – Updated Results from a Registry Study,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Sultan Haider is an andrology and urology resident at Gesundheit Nord, Bremen, Germany.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.